Literature DB >> 7521160

A putative sirolimus (rapamycin) effector protein.

Y Chen1, H Chen, A E Rhoad, L Warner, T J Caggiano, A Failli, H Zhang, C L Hsiao, K Nakanishi, K L Molnar-Kimber.   

Abstract

Sirolimus (rapamycin), a new immunosuppressive drug, inhibits proliferation of a wide spectrum of T and B cells. The immunosuppressive mechanism of sirolimus is still unclear. We recently isolated a membrane associated protein with an apparent molecular weight of 210 kDa, p210, from cultured Molt 4 cells and BJAB cells and from normal human T cells using an affinity matrix method. The p210 binds to sirolimus:FKBP12 complex, but only at background levels to FKBP12 alone, to FK506:FKBP12 complex, or sirolimus-biotin alone. Among the sirolimus analogs tested, the binding ability of p210 to drug:FKBP12 complexes correlates with the immunosuppressive activity of the drugs, suggesting that p210 is the sirolimus effector protein.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7521160     DOI: 10.1006/bbrc.1994.2140

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

Review 1.  The target of rapamycin (TOR) proteins.

Authors:  B Raught; A C Gingras; N Sonenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

Review 2.  mTOR signaling in cancer cell motility and tumor metastasis.

Authors:  Hongyu Zhou; Shile Huang
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2010       Impact factor: 1.807

Review 3.  Role of mTOR signaling in tumor cell motility, invasion and metastasis.

Authors:  Hongyu Zhou; Shile Huang
Journal:  Curr Protein Pept Sci       Date:  2011-02       Impact factor: 3.272

4.  Chemical genetics: reshaping biology through chemistry.

Authors:  Stefan Florian; Stefan Hümmer; Mario Catarinella; Thomas U Mayer
Journal:  HFSP J       Date:  2007-07-12

Review 5.  Updates of mTOR inhibitors.

Authors:  Hongyu Zhou; Yan Luo; Shile Huang
Journal:  Anticancer Agents Med Chem       Date:  2010-09       Impact factor: 2.505

6.  Comparison of effects of sirolimus on cytokine dependent and cytokine independent proliferation.

Authors:  K L Molnar-Kimber; A Rhoad; L Warner; H Chen; S N Sehgal
Journal:  Inflamm Res       Date:  1995-08       Impact factor: 4.575

Review 7.  The complexes of mammalian target of rapamycin.

Authors:  Hongyu Zhou; Shile Huang
Journal:  Curr Protein Pept Sci       Date:  2010-09       Impact factor: 3.272

8.  A simple and efficient route to the FKBP-binding domain from rapamycin.

Authors:  Wei Li; Shridhar Bhat; Jun O Liu
Journal:  Tetrahedron Lett       Date:  2011-09-28       Impact factor: 2.415

9.  Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling.

Authors:  Valerie I Brown; Junjie Fang; Keith Alcorn; Rosalind Barr; Jenny M Kim; Robert Wasserman; Stephan A Grupp
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

10.  Tumor growth effects of rapamycin on human biliary tract cancer cells.

Authors:  Matthias Heuer; Nici M Dreger; Vito R Cicinnati; Christian Fingas; Benjamin Juntermanns; Andreas Paul; Gernot M Kaiser
Journal:  Eur J Med Res       Date:  2012-06-21       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.